TCF12 enhances angiogenesis and affects sorafenib response in liver cancer via HIF-1α interaction

Transcription factor 12 (TCF12), a member of the basic Helix-Loop-Helix (bHLH) protein family, plays a crucial role in regulating cell growth and differentiation. It has been implicated in the development and progression of malignant tumors; however, its specific mechanisms in vascularization and d...

Full description

Saved in:
Bibliographic Details
Main Authors: Yuanbin Chen, Xiaolong Wang, Jin Chen, Min Dai, Xinyue Zhang, Jie Yin, Xiao He
Format: Article
Language:English
Published: Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina 2025-04-01
Series:Biomolecules & Biomedicine
Subjects:
Online Access:http://www.bjbms.org/ojs/index.php/bjbms/article/view/12022
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850269049607421952
author Yuanbin Chen
Xiaolong Wang
Jin Chen
Min Dai
Xinyue Zhang
Jie Yin
Xiao He
author_facet Yuanbin Chen
Xiaolong Wang
Jin Chen
Min Dai
Xinyue Zhang
Jie Yin
Xiao He
author_sort Yuanbin Chen
collection DOAJ
description Transcription factor 12 (TCF12), a member of the basic Helix-Loop-Helix (bHLH) protein family, plays a crucial role in regulating cell growth and differentiation. It has been implicated in the development and progression of malignant tumors; however, its specific mechanisms in vascularization and drug resistance in liver cancer remain poorly understood. This study aims to explore how the interaction between TCF12 and Hypoxia-Inducible Factor 1-alpha (HIF-1α) affects vascularization and drug sensitivity in liver cancer. Using bioinformatics analysis (n = 374 TCGA samples and n = 50 clinical specimens), we assessed TCF12 expression levels in liver cancer and evaluated their association with patient prognosis. Gene Set Enrichment Analysis (GSEA) was employed to identify related signaling pathways. The expression of TCF12 in liver cancer tissues was examined via Western blotting and immunohistochemistry, while Kaplan-Meier survival analysis was used to analyze the relationship between TCF12 expression and overall survival. Functional assays—including scratch wound repair, tube formation, and endothelial cell permeability tests—were conducted to assess TCF12’s role in angiogenesis. Cell viability assays were performed to evaluate the impact of TCF12 on sorafenib sensitivity, and co-immunoprecipitation experiments were carried out to investigate the interaction between TCF12 and HIF-1α. Our bioinformatics analysis revealed that both TCF12 and HIF-1α are significantly overexpressed in liver cancer and are associated with poor prognosis. Immunohistochemical staining showed a positive correlation between TCF12 expression and the vascularization marker CD31. Furthermore, survival analysis demonstrated that patients with elevated TCF12 expression had significantly shorter overall survival. Functional assays indicated that TCF12 knockdown suppressed blood vessel formation and reduced endothelial cell permeability. Moreover, reducing TCF12 expression increased the sensitivity of liver cancer cells to sorafenib. Notably, overexpression of HIF-1α reversed these effects, and co-immunoprecipitation experiments confirmed a direct interaction between TCF12 and HIF-1α. In summary, this study demonstrates that TCF12 is highly expressed in liver cancer and is associated with poor prognosis. TCF12 promotes angiogenesis by stabilizing HIF-1α and modulates tumor sensitivity to sorafenib, highlighting its potential as a therapeutic target in liver cancer.
format Article
id doaj-art-3898f00e3b3f440ea7473e8cd85e1cd1
institution OA Journals
issn 2831-0896
2831-090X
language English
publishDate 2025-04-01
publisher Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina
record_format Article
series Biomolecules & Biomedicine
spelling doaj-art-3898f00e3b3f440ea7473e8cd85e1cd12025-08-20T01:53:16ZengAssociation of Basic Medical Sciences of Federation of Bosnia and HerzegovinaBiomolecules & Biomedicine2831-08962831-090X2025-04-0110.17305/bb.2025.12022TCF12 enhances angiogenesis and affects sorafenib response in liver cancer via HIF-1α interactionYuanbin Chen0https://orcid.org/0000-0002-6558-0638Xiaolong Wang1Jin Chen2Min Dai3Xinyue Zhang4Jie Yin5Xiao He6Department of General Surgery, Affiliated Haian Hospital of Nantong University, Nantong, ChinaDepartment of General Surgery, Affiliated Haian Hospital of Nantong University, Nantong, ChinaDepartment of General Surgery, Affiliated Haian Hospital of Nantong University, Nantong, ChinaDepartment of General Surgery, Affiliated Haian Hospital of Nantong University, Nantong, ChinaDepartment of General Surgery, Affiliated Haian Hospital of Nantong University, Nantong, ChinaDepartment of General Surgery, Affiliated Haian Hospital of Nantong University, Nantong, ChinaDepartment of General Surgery, The Second People’s Hospital of Nantong, Nantong, China Transcription factor 12 (TCF12), a member of the basic Helix-Loop-Helix (bHLH) protein family, plays a crucial role in regulating cell growth and differentiation. It has been implicated in the development and progression of malignant tumors; however, its specific mechanisms in vascularization and drug resistance in liver cancer remain poorly understood. This study aims to explore how the interaction between TCF12 and Hypoxia-Inducible Factor 1-alpha (HIF-1α) affects vascularization and drug sensitivity in liver cancer. Using bioinformatics analysis (n = 374 TCGA samples and n = 50 clinical specimens), we assessed TCF12 expression levels in liver cancer and evaluated their association with patient prognosis. Gene Set Enrichment Analysis (GSEA) was employed to identify related signaling pathways. The expression of TCF12 in liver cancer tissues was examined via Western blotting and immunohistochemistry, while Kaplan-Meier survival analysis was used to analyze the relationship between TCF12 expression and overall survival. Functional assays—including scratch wound repair, tube formation, and endothelial cell permeability tests—were conducted to assess TCF12’s role in angiogenesis. Cell viability assays were performed to evaluate the impact of TCF12 on sorafenib sensitivity, and co-immunoprecipitation experiments were carried out to investigate the interaction between TCF12 and HIF-1α. Our bioinformatics analysis revealed that both TCF12 and HIF-1α are significantly overexpressed in liver cancer and are associated with poor prognosis. Immunohistochemical staining showed a positive correlation between TCF12 expression and the vascularization marker CD31. Furthermore, survival analysis demonstrated that patients with elevated TCF12 expression had significantly shorter overall survival. Functional assays indicated that TCF12 knockdown suppressed blood vessel formation and reduced endothelial cell permeability. Moreover, reducing TCF12 expression increased the sensitivity of liver cancer cells to sorafenib. Notably, overexpression of HIF-1α reversed these effects, and co-immunoprecipitation experiments confirmed a direct interaction between TCF12 and HIF-1α. In summary, this study demonstrates that TCF12 is highly expressed in liver cancer and is associated with poor prognosis. TCF12 promotes angiogenesis by stabilizing HIF-1α and modulates tumor sensitivity to sorafenib, highlighting its potential as a therapeutic target in liver cancer. http://www.bjbms.org/ojs/index.php/bjbms/article/view/12022Transcription factor 12TCF12Hypoxia-Inducible Factor 1-alphaHIF-1αangiogenesissorafenib
spellingShingle Yuanbin Chen
Xiaolong Wang
Jin Chen
Min Dai
Xinyue Zhang
Jie Yin
Xiao He
TCF12 enhances angiogenesis and affects sorafenib response in liver cancer via HIF-1α interaction
Biomolecules & Biomedicine
Transcription factor 12
TCF12
Hypoxia-Inducible Factor 1-alpha
HIF-1α
angiogenesis
sorafenib
title TCF12 enhances angiogenesis and affects sorafenib response in liver cancer via HIF-1α interaction
title_full TCF12 enhances angiogenesis and affects sorafenib response in liver cancer via HIF-1α interaction
title_fullStr TCF12 enhances angiogenesis and affects sorafenib response in liver cancer via HIF-1α interaction
title_full_unstemmed TCF12 enhances angiogenesis and affects sorafenib response in liver cancer via HIF-1α interaction
title_short TCF12 enhances angiogenesis and affects sorafenib response in liver cancer via HIF-1α interaction
title_sort tcf12 enhances angiogenesis and affects sorafenib response in liver cancer via hif 1α interaction
topic Transcription factor 12
TCF12
Hypoxia-Inducible Factor 1-alpha
HIF-1α
angiogenesis
sorafenib
url http://www.bjbms.org/ojs/index.php/bjbms/article/view/12022
work_keys_str_mv AT yuanbinchen tcf12enhancesangiogenesisandaffectssorafenibresponseinlivercancerviahif1ainteraction
AT xiaolongwang tcf12enhancesangiogenesisandaffectssorafenibresponseinlivercancerviahif1ainteraction
AT jinchen tcf12enhancesangiogenesisandaffectssorafenibresponseinlivercancerviahif1ainteraction
AT mindai tcf12enhancesangiogenesisandaffectssorafenibresponseinlivercancerviahif1ainteraction
AT xinyuezhang tcf12enhancesangiogenesisandaffectssorafenibresponseinlivercancerviahif1ainteraction
AT jieyin tcf12enhancesangiogenesisandaffectssorafenibresponseinlivercancerviahif1ainteraction
AT xiaohe tcf12enhancesangiogenesisandaffectssorafenibresponseinlivercancerviahif1ainteraction